VEGFA and COVID-19: Binds circulating VEGF and blocks its receptor binding, effectively inhibiting downstream signaling and preventing angiogenesis, lymphangiogenesis, and potential edematous effect. VEGF is upregulated in COVID-19, and thus may contribute to pulmonary edema, leading to ARDS and ALI.